| Monoclonal antibodies and other biologic agents in the treatment of asthma. | |
| | |
MedLine Citation:
|
PMID: 20065638 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Asthma represents a syndrome of airway inflammatory diseases with complex pathology. The immunologic pathogenesis is being increasingly revealed and provides opportunity for targeted biological intervention. Current experience with immunomodulators as targeted therapy in asthma is described in this literature review. Targeted therapies have included strategies to activate dendritic cells through the TLR-9 receptors, to interrupt the action of T(H)2 cytokines with cytokine blockers and monoclonal antibodies, to promote development of T(H)1 responses, to block IgE mediated pathways and to block TNFalpha. Omalizumab is the only biological therapy that has an approved indication in asthma at this time. An improved understanding of the heterogeneity of asthma should allow for specific targeting of different disease phenotypes specific therapies including immunomodulators. |
| | |
Authors:
|
Aidan A Long |
Related Documents
:
|
3533588 - Asthma and the role of inflammation. 7797058 - Mediator assays and modulation of inflammation in asthma: introduction. 18490768 - Nicotine primarily suppresses lung th2 but not goblet cell and muscle cell responses to... 20796248 - Allergy is an important factor in asthma exacerbation: a pro/con debate. 15795118 - Regulatory roles of sex hormones in cutaneous biology and immunology. 15096178 - Interferon-gamma activation of polymorphonuclear neutrophil function. |
Publication Detail:
|
Type: Journal Article; Review Date: 2009-05-04 |
Journal Detail:
|
Title: mAbs Volume: 1 ISSN: 1942-0870 ISO Abbreviation: MAbs Publication Date: 2009 May-Jun |
Date Detail:
|
Created Date: 2010-01-12 Completed Date: 2010-06-10 Revised Date: 2010-11-16 |
Medline Journal Info:
|
Nlm Unique ID: 101479829 Medline TA: MAbs Country: United States |
Other Details:
|
Languages: eng Pagination: 237-46 Citation Subset: IM |
Affiliation:
|
Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA 02114, USA. aalong@mgh.harvard.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antibodies, Monoclonal / therapeutic use Asthma / immunology, therapy* Biological Factors / immunology, therapeutic use* Cytokines / antagonists & inhibitors Dendritic Cells / drug effects*, immunology Humans Immunoglobulin E / immunology Immunomodulation* Th2 Cells / drug effects*, immunology Toll-Like Receptor 9 / agonists Tumor Necrosis Factor-alpha / antagonists & inhibitors |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Biological Factors; 0/Cytokines; 0/Toll-Like Receptor 9; 0/Tumor Necrosis Factor-alpha; 0/omalizumab; 37341-29-0/Immunoglobulin E |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Second International Conference on Accelerating Biopharmaceutical Development: March 9-12, 2009, Cor...
Next Document: Golimumab.